Premium
Antiarrhythmic properties of triamterene derivatives in the coronary artery ligated rat model
Author(s) -
Busch A. E.,
Ullrich F.,
Mutschler E.
Publication year - 1991
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.2503241114
Subject(s) - triamterene , quinidine , pharmacology , sotalol , chemistry , lidocaine , amiodarone , diuretic , potassium , medicine , anesthesia , atrial fibrillation , hydrochlorothiazide , blood pressure , organic chemistry
Abstract Triamterene and several triamterene derivatives (Table 1) were tested for antiarrhythmic activity in the coronary artery ligated and reperfused (CAL‐R) rat. The class‐III antiarrhythmic drugs (±)‐sotalol and amiodarone, the class‐I antiarrhythmics lidocaine and quinidine as well as the potassium sparing diuretic amilorid were used as reference drugs. Triamterene at the highest dose (30 μmol/kg) revealed a 100% protection against ventricular fibrillation (VF), whereas at 10 μmol/kg no antiarrhythmic activity for triamterene could be found. For compound 4 (10 μmol/kg) a 75% protection against VF could be demonstrated, while 2 , 3 , and 5 revealed only a 25% protection. Compared to the reference drugs, triamterene and the derivatives 2–5 are more potent than (±)‐sotalol, but less potent than lidocaine, quinidine and amiodarone. For amiloride as well as for the potent potassium retaining triamterene derivative 6 no antiarrhythmic activity could be shown. Therefore, we conclude different mechanisms responsible for the potassium sparing and antiarrhythmic properties of triamterene and its derivatives.